SARS-CoV-2 mucosal neutralising immunity after vaccination

Edward J Carr¹, Guilia Dowgier², David Greenwood³, Lou S Herman², Agnieszka Hobbs², Martina Ragno², Phoebe Stevenson-Leggett², Joshua Gahir⁴, Hermaleigh Townsley³, Ruth Harvey⁵, Chris Bailey³, Ashley S Fowler³, Murad Miah³, Callie Smith³, Mauro Miranda³, Philip Bawumia³, Harriet V Mears³, Lorin Adams⁵, Emine Hatipoglu⁶, Nicola O'Reilly³, Scott Warchal³, Chelsea Sawyer³, Karen Ambrose³, Amy Strange³, Gavin Kelly³, Rupert Beale⁷, Padmasayee Papineni⁸, Tumena Corrah⁸, Richard Gilson⁹, Steve Gamblin³, George Kassiotis¹⁰, Vincenzo Libri¹¹, Bryan Williams¹¹, Charles Swanton⁶, Sonia Gandhi⁶, David L V Bauer¹², Emma Wall⁴, Mary Y Wu¹³

Affiliations

¹ UCL Department of Renal Medicine, Royal Free Hospital, Rowland Hill Street, London, UK; The Francis Crick Institute, London NW1 1AT, UK.
² COVID Surveillance Unit, London NW1 1AT, UK.
³ The Francis Crick Institute, London NW1 1AT, UK.
⁴ The Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
⁵ Worldwide Influenza Centre, London NW1 1AT, UK.
⁶ The Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
⁷ The Francis Crick Institute, London NW1 1AT, UK; The Francis Crick Institute, London NW1 1AT, UK; Genotype-to-Phenotype UK National Virology Consortium, London, UK.
⁸ London Northwest University Healthcare NHS Trust, London, UK.
⁹ Central and North West London NHS Foundation Trust, London, UK; University College London, London, UK.
¹⁰ The Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK.
¹¹ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
¹² The Francis Crick Institute, London NW1 1AT, UK; Genotype-to-Phenotype UK National Virology Consortium, London, UK.
¹³ COVID Surveillance Unit, London NW1 1AT, UK; The Francis Crick Institute, London NW1 1AT, UK. Electronic address: mary.wu@crick.ac.uk.

PMID: 38070528
DOI: 10.1016/S1473-3099(23)00705-3

SARS-CoV-2 mucosal neutralising immunity after vaccination

Edward J Carr et al. Lancet Infect Dis. 2024 Jan.

. 2024 Jan;24(1):e4-e5.

doi: 10.1016/S1473-3099(23)00705-3. Epub 2023 Dec 6.

Authors

Affiliations

¹ UCL Department of Renal Medicine, Royal Free Hospital, Rowland Hill Street, London, UK; The Francis Crick Institute, London NW1 1AT, UK.
² COVID Surveillance Unit, London NW1 1AT, UK.
³ The Francis Crick Institute, London NW1 1AT, UK.
⁴ The Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
⁵ Worldwide Influenza Centre, London NW1 1AT, UK.
⁶ The Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
⁷ The Francis Crick Institute, London NW1 1AT, UK; The Francis Crick Institute, London NW1 1AT, UK; Genotype-to-Phenotype UK National Virology Consortium, London, UK.
⁸ London Northwest University Healthcare NHS Trust, London, UK.
⁹ Central and North West London NHS Foundation Trust, London, UK; University College London, London, UK.
¹⁰ The Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK.
¹¹ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
¹² The Francis Crick Institute, London NW1 1AT, UK; Genotype-to-Phenotype UK National Virology Consortium, London, UK.
¹³ COVID Surveillance Unit, London NW1 1AT, UK; The Francis Crick Institute, London NW1 1AT, UK. Electronic address: mary.wu@crick.ac.uk.

PMID: 38070528
DOI: 10.1016/S1473-3099(23)00705-3

No abstract available

PubMed Disclaimer

Conflict of interest statement

CSw reports interests unrelated to this Correspondence: grants from AstraZeneca, Bristol-Myers Squibb, Ono Pharmaceutical, Boehringer Ingelheim, Roche-Ventana, Pfizer, and Invitae (formerly Archer Dx); personal fees from Genentech, the Sarah Canon Research Institute, Medicxi, Metabomed, Novartis, Relay Therapeutics, CICoR, SAGA Diagnostics, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, Bristol-Myers Squibb, Illumina, GlaxoSmithKline, MSD, Pfizer, Roche-Ventana, and Cancer Research UK; and stock options from Apogen Biotech and Epic Biosciences. DLVB reports grants from AstraZeneca unrelated to this Correspondence. EJC declares unpaid membership of the UK Kidney Association Infection Prevention and Control Committee unrelated to this Correspondence. All other authors declare no competing interests. The Legacy study was approved by London Camden and Kings Cross Health Research Authority Research and Ethics committee (20/HRA/4717).

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

MR/W005611/1/MRC_/Medical Research Council/United Kingdom

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 mucosal neutralising immunity after vaccination

Affiliations

SARS-CoV-2 mucosal neutralising immunity after vaccination

Authors

Affiliations

Conflict of interest statement

Publication types

MeSH terms

Substances

Grants and funding